SPIRITT: A Randomized, Multicenter, Phase II Study of Panitumumab with FOLFIRI and Bevacizumab with FOLFIRI as Second-Line Treatment in Patients with Unresectable Wild Type KRAS Metastatic Colorectal Cancer

J. Randolph Hecht; Allen Cohn; Shaker Dakhil; Mansoor Saleh; Bilal Piperdi; Mika Cline-Burkhardt; Ying Tian; William Y. Go

doi:10.1016/j.clcc.2014.12.009

SPIRITT: A Randomized, Multicenter, Phase II Study of Panitumumab with FOLFIRI and Bevacizumab with FOLFIRI as Second-Line Treatment in Patients with Unresectable Wild Type KRAS Metastatic Colorectal Cancer

Clinical Colorectal Cancer ◽

10.1016/j.clcc.2014.12.009 ◽

2015 ◽

Vol 14 (2) ◽

pp. 72-80 ◽

Cited By ~ 50

Author(s):

J. Randolph Hecht ◽

Allen Cohn ◽

Shaker Dakhil ◽

Mansoor Saleh ◽

Bilal Piperdi ◽

...

Keyword(s):

Colorectal Cancer ◽

Metastatic Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Line Treatment ◽

Second Line ◽

Wild Type ◽

Multicenter Phase

Download Full-text

420P A single-arm, multicenter, phase II study of anlotinib combined with CAPEOX as first-line treatment in RAS/BRAF wild-type unresectable metastatic colorectal cancer (ALTER-C002)

Annals of Oncology ◽

10.1016/j.annonc.2021.08.941 ◽

2021 ◽

Vol 32 ◽

pp. S545

Author(s):

K. Ding ◽

Y. Liu ◽

J. Du ◽

Y. Zhu ◽

D. Xu ◽

...

Keyword(s):

Colorectal Cancer ◽

Metastatic Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Line Treatment ◽

Wild Type ◽

First Line ◽

Multicenter Phase ◽

First Line Treatment ◽

Unresectable Metastatic Colorectal Cancer

Download Full-text

172PD Final analysis: Phase II trial of irinotecan/S-1/cetuximab (IRIS/Cet) as second line treatment in patients with KRAS exon2 wild type metastatic colorectal cancer: HGCSG0902. Comparison of administration interval in cetuximab treatment

Annals of Oncology ◽

10.1016/s0923-7534(21)00330-6 ◽

2016 ◽

Vol 27 ◽

pp. ix54

Author(s):

T. Ando ◽

S. Yuki ◽

H. Nakatsumi ◽

T. Muranaka ◽

A. Hosokawa ◽

...

Keyword(s):

Colorectal Cancer ◽

Metastatic Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Final Analysis ◽

Line Treatment ◽

Second Line ◽

Wild Type ◽

Analysis Phase ◽

Administration Interval

Download Full-text

FOLFIRI plus panitumumab as second-line treatment in mutated RAS metastatic colorectal cancer patients who converted to wild type RAS after receiving first-line FOLFOX/CAPOX plus bevacizumab-based treatment: Phase II CONVERTIX trial

Annals of Oncology ◽

10.1093/annonc/mdz155.088 ◽

2019 ◽

Vol 30 ◽

pp. iv23-iv24 ◽

Cited By ~ 3

Author(s):

A. Fernández Montes ◽

N. Martinez Lago ◽

J. De la Cámara Gómez ◽

M. Covela Rúa ◽

A. Cousillas Castiñeiras ◽

...

Keyword(s):

Colorectal Cancer ◽

Metastatic Colorectal Cancer ◽

Cancer Patients ◽

Phase Ii ◽

Treatment Phase ◽

Line Treatment ◽

Second Line ◽

Wild Type ◽

First Line ◽

Colorectal Cancer Patients

Download Full-text

Multicenter open-label randomized phase II study of second-line panitumumab and irinotecan with or without fluoropyrimidines in patients with KRAS wild-type metastatic colorectal cancer (PACIFIC study)

Medical Oncology ◽

10.1007/s12032-019-1254-4 ◽

2019 ◽

Vol 36 (6) ◽

Cited By ~ 1

Author(s):

Naoki Nagata ◽

Hiromichi Maeda ◽

Keiichiro Ishibashi ◽

Keiji Hirata ◽

Akitaka Makiyama ◽

...

Keyword(s):

Colorectal Cancer ◽

Metastatic Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Second Line ◽

Wild Type ◽

Open Label ◽

Randomized Phase Ii

Download Full-text

An open-label multicenter phase II study of oral lapatinib (GW572016) as single agent, second-line therapy in patients with metastatic colorectal cancer

Journal of Clinical Oncology ◽

10.1200/jco.2005.23.16_suppl.3583 ◽

2005 ◽

Vol 23 (16_suppl) ◽

pp. 3583-3583 ◽

Cited By ~ 22

Author(s):

A. L. A. Fields ◽

D. A. Rinaldi ◽

C. A. Henderson ◽

C. J. Germond ◽

L. Chu ◽

...

Keyword(s):

Colorectal Cancer ◽

Metastatic Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Single Agent ◽

Second Line ◽

Open Label ◽

Second Line Therapy ◽

Multicenter Phase ◽

Line Therapy

Download Full-text

S-1 and irinotecan plus bevacizumab as second-line chemotherapy for patients with oxaliplatin-refractory metastatic colorectal cancer: a multicenter phase II study in Japan (KSCC1102)

International Journal of Clinical Oncology ◽

10.1007/s10147-015-0943-z ◽

2016 ◽

Vol 21 (4) ◽

pp. 705-712 ◽

Cited By ~ 3

Author(s):

Yuji Miyamoto ◽

Akihito Tsuji ◽

Hiroaki Tanioka ◽

Soichiro Maekawa ◽

Hirofumi Kawanaka ◽

...

Keyword(s):

Colorectal Cancer ◽

Metastatic Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Second Line ◽

Second Line Chemotherapy ◽

Multicenter Phase ◽

Line Chemotherapy

Download Full-text

A multicenter phase II study of irinotecan (CPT-11) alternated with 5-fluorouracil and leucovorin as first-line treatment of patients with metastatic colorectal cancer

Cancer Chemotherapy and Pharmacology ◽

10.1007/s00280-003-0601-4 ◽

2003 ◽

Vol 52 (4) ◽

pp. 339-345 ◽

Cited By ~ 3

Author(s):

Juan José Reina ◽

Jorge Aparicio ◽

Javier Salvador ◽

José María Puerto Pica ◽

Antonio Rueda ◽

...

Keyword(s):

Colorectal Cancer ◽

Metastatic Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Line Treatment ◽

First Line ◽

Multicenter Phase ◽

First Line Treatment

Download Full-text

469P Efficacy and safety of anlotinib combined with CAPEOX in first-line treatment of patients with RAS and BRAF wild-type unresectable metastatic colorectal cancer - A single-arm, multi-center, phase II study (ALTER-C-002 trial)

Annals of Oncology ◽

10.1016/j.annonc.2020.08.580 ◽

2020 ◽

Vol 31 ◽

pp. S440

Author(s):

K. Ding ◽

Y. Liu ◽

J. Chen ◽

J. Ying ◽

Q. Xu ◽

...

Keyword(s):

Colorectal Cancer ◽

Metastatic Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Line Treatment ◽

Efficacy And Safety ◽

Wild Type ◽

First Line ◽

First Line Treatment ◽

Unresectable Metastatic Colorectal Cancer

Download Full-text

Correction to: S-1 and irinotecan plus bevacizumab as second-line chemotherapy for patients with oxaliplatin-refractory metastatic colorectal cancer: a multicenter phase II study in Japan (KSCC1102)

International Journal of Clinical Oncology ◽

10.1007/s10147-017-1212-0 ◽

2017 ◽

Vol 23 (2) ◽

pp. 402-402

Author(s):

Yuji Miyamoto ◽

Akihito Tsuji ◽

Hiroaki Tanioka ◽

Soichiro Maekawa ◽

Hirofumi Kawanaka ◽

...

Keyword(s):

Colorectal Cancer ◽

Metastatic Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Second Line ◽

Second Line Chemotherapy ◽

Multicenter Phase ◽

Line Chemotherapy

Download Full-text

Capecitabine in combination with oxaliplatin and bevacizumab (AXELOX) as 1st line treatment for fit and vulnerable elderly patients (aged >70 years) with metastatic colorectal cancer (mCRC): a multicenter phase II study of the Hellenic Oncology Research Group (HORG)

BMC Cancer ◽

10.1186/1471-2407-14-277 ◽

2014 ◽

Vol 14 (1) ◽

Cited By ~ 8

Author(s):

Lambros Vamvakas ◽

Alexios Matikas ◽

Athanasios Karampeazis ◽

Dora Hatzidaki ◽

Stelios Kakolyris ◽

...

Keyword(s):

Colorectal Cancer ◽

Elderly Patients ◽

Metastatic Colorectal Cancer ◽

Phase Ii ◽

Research Group ◽

Phase Ii Study ◽

Line Treatment ◽

Oncology Research ◽

Multicenter Phase ◽

Vulnerable Elderly

Download Full-text